Department of Orthopedics, Uppsala University, Uppsala, Sweden.
J Biomed Mater Res A. 2013 Aug;101(8):2322-31. doi: 10.1002/jbm.a.34526. Epub 2013 Jan 28.
Treatment of osteoporotic fractures with conventional surgical methods is associated with a high rate of complications. Intense search for new treatment options includes development of specific biomaterials aimed to be part of the surgical armamentarium. Strontium doped calcium phosphate spheres (SrCPS) is a new material that might be of interest due to the influence on osteoclast and osteoblast activity. In the present study, we successfully constructed hollow spherical SrCPS particles with a diameter of ~700 nm and shell thickness of ~150 nm. The Sr content was about 20 wt %. Cell viability and cytotoxicity were investigated in vitro with concentrations from 0 to 1000 μg/mL of SrCPS in medium extract in a day chase study. The in vivo biocompatibility was tested in a delayed bone-healing model in a rat vertebral defect by histology, μCT, and nanoSPECT. The SrCPS showed no toxicity in vitro with comparable cell number in all concentrations. Increased metabolism was seen in the cell viability study in cells exposed to 400 and 600 μg/mL. SPECT showed good biocompatibility with no local adverse effects and an increased osteoblast activity as compared to adjacent vertebra. SrCPS implantation induced bone formation and resulted in complete resorption and defect consolidation.
采用传统手术方法治疗骨质疏松性骨折会导致较高的并发症发生率。人们积极寻求新的治疗方案,包括开发旨在成为手术手段一部分的特定生物材料。锶掺杂磷酸钙球(SrCPS)是一种新材料,由于其对破骨细胞和成骨细胞活性的影响,可能具有研究价值。在本研究中,我们成功构建了直径约 700nm、壳厚约 150nm 的中空球形 SrCPS 颗粒,Sr 含量约为 20wt%。通过逐日进行介质提取物中浓度为 0 至 1000μg/ml 的 SrCPS 细胞活力和细胞毒性体外研究。通过组织学、μCT 和 nanoSPECT 在大鼠椎骨缺损延迟骨愈合模型中测试体内生物相容性。SrCPS 在体外无毒性,所有浓度的细胞数量相当。暴露于 400μg/ml 和 600μg/ml 的细胞代谢研究中,细胞活力增加。与相邻椎体相比,SPECT 显示出良好的生物相容性,没有局部不良反应,成骨细胞活性增加。SrCPS 植入诱导骨形成,导致完全吸收和缺损愈合。